Protagenic Therapeutics appoints William Nichols Jr. as president
#Protagenic Therapeutics #William Nichols #President Appointment #OTC Trading #Phase 1 Results #Biotechnology #SEC Filing #Nasdaq Delisting
📌 Key Takeaways
- William Nichols Jr. appointed as president of Protagenic Therapeutics with board approval on February 3, 2026
- Nichols brings experience from biotech and pharmaceutical companies including bluebird bio, Dova Pharmaceuticals, and Bristol-Myers Squibb
- Company transitioning to OTC market after Nasdaq delisting due to non-compliance with listing requirements
- Positive safety results reported from Phase 1 study of PT00114 for stress-related neuropsychiatric conditions
📖 Full Retelling
Protagenic Therapeutics, Inc. (OTC:PTIX) announced the appointment of William Nichols, Jr. as president of the company on March 3, 2026, according to a recent SEC filing, with the board approving the leadership change on February 3, 2026, to strengthen the biotechnology firm's commercial operations following its delisting from Nasdaq. Nichols, age 51, brings extensive experience from senior commercial leadership roles at prominent biotechnology and pharmaceutical companies including bluebird bio, Dova Pharmaceuticals (now Sobi), and Bristol-Myers Squibb. Under the terms of his employment agreement, Nichols will receive an annual base salary of $350,000, plus an annual target bonus equal to 40% of his base salary, along with an option grant representing approximately 1.0% of Protagenic Therapeutics' fully diluted share count. The company emphasized there were no arrangements or understandings with any other person regarding Nichols' selection as an officer, and no family relationships between Nichols and any of the company's directors or executive officers. Additionally, Protagenic Therapeutics announced that its common stock and common stock warrants will transition to trading on the over-the-counter market under the symbols PTIX and PTIXW, respectively, following Nasdaq's decision to delist the company's securities due to non-compliance with specific listing requirements, including minimum stockholders' equity and timely filing of periodic reports. The biotechnology firm also reported positive topline safety results from its Phase 1 Multiple Dose study of PT00114, a synthetic analogue targeting stress-related neuropsychiatric conditions, which was well tolerated at all dose levels with no serious adverse events observed in healthy volunteers.
🏷️ Themes
Leadership Change, Market Transition, Clinical Progress
📚 Related People & Topics
Biotechnology
Use of living systems and organisms to develop or make useful products
Biotechnology is a multidisciplinary field that involves the integration of natural sciences and engineering sciences in order to achieve the application of organisms and parts thereof for products and services. Specialists in the field are known as biotechnologists. The term biotechnology was first...
William Nichols
Topics referred to by the same term
William or Bill Nichols may refer to: William Nichols (English priest), Dean of Chester, 1644–1657 William Nichols, secretary of John Fell, 17th century clergyman William Nichols (mariner) (fl. 1758–1780), English sea captain William Nichols (architect) (1780–1853), English-born American architect ...
Entity Intersection Graph
Connections for Biotechnology:
🌐
Insider trading
6 shared
🏢
Ginkgo Bioworks
2 shared
🌐
Volatility (finance)
2 shared
🌐
SEC filing
2 shared
🏢
Pacific Biosciences
1 shared
Mentioned Entities
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Gold hands back some gains as stronger dollar weighs; Iran conflict in spotlight Oil extends surge on concerns surrounding Strait of Hormuz closure Futures drop, oil prices climb amid Iran conflict - what’s moving markets Navigate shifting markets with investor-grade confidence - YEAR’S LOWEST PRICE NOW FLASH SALE (South Africa Philippines Nigeria) FLASH SALE Protagenic Therapeutics appoints William Nichols Jr. as president By Investing.com SEC Filings Published 03/03/2026, 06:23 AM Protagenic Therapeutics appoints William Nichols Jr. as president 0 PTIX -3.01% Protagenic Therapeutics , Inc. (OTC:PTIX) announced the appointment of William Nichols, Jr. as president of the company, according to a press release statement based on a recent SEC filing. The board of directors approved the appointment on February 3, 2026. Nichols, age 51, brings experience from previous senior commercial leadership roles at biotechnology and pharmaceutical companies including bluebird bio, Dova Pharmaceuticals (now Sobi), and Bristol-Myers Squibb. Under the terms of his employment agreement, Nichols will receive an annual base salary of $350,000. He is also eligible for an annual target bonus equal to 40% of his base salary. The agreement includes an option grant representing approximately 1.0% of Protagenic Therapeutics’ fully diluted share count. The company stated there were no arrangements or understandings with any other person regarding Nichols’ selection as an officer. There are no family relationships between Nichols and any of the company’s directors or executive officers, and no transactions requiring disclosure under Item 404 of Regulation S-K. Protagenic Therapeutics’ common stock and common stock warrants are traded on the OTC Markets under the symbols PTIX and PTIXW, respectively. All information is based on a statement from the company’s SEC Form 8-K filing. In other recent news, Protagenic Therapeutics Inc. has annou...
Read full article at source